September 30, 2021

Notice on the Completion of Disposal of Treasury Shares for

the Post-delivery Type Performance-Linked Stock Remuneration System

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Shigeo Taniuchi; hereinafter, the "Company") announced that the disposal of treasury shares (hereinafter, the "disposal") related to the Post-delivery Type Performance-linked stock remuneration system was completed on September 30, 2021 based on the Board of Directors resolution of September 1, 2021, details of which are provided below. (Please see Santen's release on "Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration System" dated September 1, 2021 for more details)

Details

Outline of the disposal

(1)

Type and number of shares

37,136 common shares of the Company's common stock

to be disposed of

(2)

Disposal price

1,640 yen per share

(3)

Total amount of share disposal

60,903,040 yen

Disposal recipients, the number of

3 Directors (excludes outside directors): 15,584 shares

(4)

such recipients and the number of

10 Corporate officers (excludes retired and resigned corporate

shares to be disposed of

officers ): 18,247 shares

3 retired and resigned Corporate Officers: 3,305 shares

(5)

Disposal date

September 30, 2021

Contact:

Kaori Itagaki

General Manager, IR Group

E-mail:ir@santen.comTel: +81-6-7664-8621

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices, and its products now reach patients in over 60 countries.

Toward realizing "WORLD VISION" (Happiness with Vision), the world Santen ultimately aspires to achieve, as a "Social Innovator", we aim to reduce the social and economic opportunity loss of people around the world caused by eye diseases and defects by orchestrating and mobilizing key technologies and players around the world.

With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.

For more information, please visit Santen's website (www.santen.com).

Attachments

  • Original document
  • Permalink

Disclaimer

Santen Pharmaceutical Co. Ltd. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 07:01:02 UTC.